181 related articles for article (PubMed ID: 35059985)
1. Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas.
Pu N; Chen Q; Yin H; Zhang J; Zhao G; Habib JR; Chen J; Yu J; Lou W; Wu W
J Gastrointest Surg; 2022 Apr; 26(4):869-886. PubMed ID: 35059985
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
3. A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma.
Sun X; Song H; Sun X; Liao C; Wang G; Xu Y; Li L; Han Y; Xu C; Wang W; Cai S; Liang H; Yu H
Cancer Invest; 2024 Mar; 42(3):226-242. PubMed ID: 38616304
[TBL] [Abstract][Full Text] [Related]
4. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.
Kandimalla R; Tomihara H; Banwait JK; Yamamura K; Singh G; Baba H; Goel A
Clin Cancer Res; 2020 Jul; 26(14):3641-3648. PubMed ID: 32234757
[TBL] [Abstract][Full Text] [Related]
5. An endoplasmic reticulum stress-related signature could robustly predict prognosis and closely associate with response to immunotherapy in pancreatic ductal adenocarcinoma.
Liu S; Hu Q; Xie Z; Chen S; Li Y; Quan N; Huang K; Li R; Fang L
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15589-15608. PubMed ID: 37653101
[TBL] [Abstract][Full Text] [Related]
6. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X
Front Immunol; 2021; 12():728062. PubMed ID: 34691034
[TBL] [Abstract][Full Text] [Related]
7. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
[TBL] [Abstract][Full Text] [Related]
8. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
9. Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma.
Xu X; Liang JH; Xu QC; Yin XY
Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102089. PubMed ID: 36707046
[TBL] [Abstract][Full Text] [Related]
10. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Tomimaru Y; Eguchi H; Inoue Y; Nagakawa Y; Ohba A; Takami H; Unno M; Yamamoto T; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Hattori S; Fujii T; Hirooka Y; Igarashi H; Kitano M; Kuroki T; Masamune A; Shimizu Y; Tani M; Tanno S; Tsuji Y; Yamaue H; Satoi S; Takeyama Y;
Cancer; 2023 Mar; 129(5):728-739. PubMed ID: 36504020
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma.
Wu M; Li X; Liu R; Yuan H; Liu W; Liu Z
J Cancer; 2020; 11(21):6299-6318. PubMed ID: 33033514
[No Abstract] [Full Text] [Related]
12. Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study.
Pu N; Wu W; Liu S; Xie Y; Yin H; Chen Q; He T; Xu Z; Wang W; Yu J; Liu L; Lou W
Int J Surg; 2023 Oct; 109(10):3137-3146. PubMed ID: 37418574
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
14. Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia.
Ren M; Feng L; Zong R; Sun H
World J Surg Oncol; 2023 Aug; 21(1):257. PubMed ID: 37605192
[TBL] [Abstract][Full Text] [Related]
15. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery.
Sergeant G; van Eijsden R; Roskams T; Van Duppen V; Topal B
BMC Cancer; 2012 Nov; 12():527. PubMed ID: 23157946
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract][Full Text] [Related]
18. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
19. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
Nicolle R; Gayet O; Duconseil P; Vanbrugghe C; Roques J; Bigonnet M; Blum Y; Elarouci N; Armenoult L; Ayadi M; de Reyniès A; Puleo F; Augustin J; Emile JF; Svrcek M; Arsenijevic T; Hammel P; Giovannini M; Grandval P; Dahan L; Moutardier V; Gilabert M; Van Laethem JL; Bachet JB; Cros J; Iovanna J; Dusetti NJ
Ann Oncol; 2021 Feb; 32(2):250-260. PubMed ID: 33188873
[TBL] [Abstract][Full Text] [Related]
20. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]